Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
142 participants
INTERVENTIONAL
2025-10-03
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Lilac Glove and Boot devices apply a low pressure across the surface of the hands and feet, respectively, to reduce access of chemotherapy to the peripheral nerves on the hands and feet. The small amount of pressure reduces the level of chemotherapy reaching the peripheral nerves, hence increasing the likelihood of nerve preservation during treatment and thus may potentially temporarily prevent the onset of moderate to severe PN symptoms induced by chemotherapy in the hands and feet while receiving treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy
NCT02088996
Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03272919
Effect of Hands and Feet Exercises on Taxane Based Chemotherapy Induced Peripheral Neuropathy in Patients With Solid Tumors
NCT07321236
Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy
NCT06627348
Identification of Chemotherapy-induced Peripheral Neuropathy
NCT07148336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
The Lilac Device
The Lilac Glove and Boot devices are wearable, non-sterile device for patients undergoing cancer treatment who wish to reduce the risk of peripheral neuropathy. Treatment with the Lilac Glove and Boot devices is administered by the healthcare professional in the healthcare environment. The Lilac Glove and Boot devices are designed for continual use; the devices must be fitted and turned on before infusion begins; the devices must be used without interruption during infusion, and for up to two (2) hours after infusion is complete.
Control
Sham device
The sham device will look, appear to function and worn for the same duration as the Lilac Device. The only difference between the devices is the level of compression applied.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Lilac Device
The Lilac Glove and Boot devices are wearable, non-sterile device for patients undergoing cancer treatment who wish to reduce the risk of peripheral neuropathy. Treatment with the Lilac Glove and Boot devices is administered by the healthcare professional in the healthcare environment. The Lilac Glove and Boot devices are designed for continual use; the devices must be fitted and turned on before infusion begins; the devices must be used without interruption during infusion, and for up to two (2) hours after infusion is complete.
Sham device
The sham device will look, appear to function and worn for the same duration as the Lilac Device. The only difference between the devices is the level of compression applied.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adults ≥ age 18 with diagnosed solid tumor cancer, who have been deemed appropriate for neo-adjuvant or adjuvant chemotherapy.
2. Planned intravenous treatment with at least 4 cycles of chemotherapy, with no planned treatment pause for surgery,
* With one of the following treatments:
* Chemotherapy regimens based on Oxaliplatin
* FOLFOX every 2 weeks
* FOLFIRINOX every 2 weeks
* Chemotherapy regimens based on single-agent Paclitaxel
* Paclitaxel weekly
* Paclitaxel every 3 weeks
* Chemotherapy regimens based on Paclitaxel + Carboplatin
* Paclitaxel weekly with Carboplatin weekly/every 3 weeks
* Paclitaxel every 3 weeks with Carboplatin every 3 weeks
3. Hands and feet size within the specified study sizing range.
4. Plan to complete taxane- or platinum-based chemotherapy in ≤ 12 months.
5. ECOG performance status 0 - 2.
6. Willing and able to sign informed consent.
7. Willing to comply with and tolerate all study procedures including:
* Wearing the Lilac Glove and Boot devices for the prescribed duration (devices to be fitted before infusion, and worn during infusion and for up to one (1) hours post infusion),
* Complete all study related questionnaires.
8. Participants must be able to complete participant specific questionnaires in the languages available to the study
Exclusion Criteria
1. Baseline peripheral neuropathy of any kind as defined by NCI CTCAE v5.0 grade \> 0.
2. Prior exposure to neurotoxic chemotherapy in the previous 1 year, counted as the period since the last neurotoxic chemotherapy treatment (e.g., taxanes, platinum agents, vinca alkaloids, or bortezomib).
3. Positive pregnancy test at baseline for participants with child bearing potential, as per standard of care.
4. Known or suspected allergy or hypersensitivity to any component of the Lilac Glove or Boot device that comes into contact with the study participant. Caution: This product contains natural rubber latex, which may cause allergic reactions.
5. Any open wounds, sores, cysts or injury on the participant's hand or on part of the upper arm where the device will be applied or on the participant's feet or part of the lower leg where the device will be applied, which in the opinion of the investigator will not be healed prior to infusion commencing or who in the opinion of the investigator will be inappropriate for inclusion in this study.
6. Clinically significant peripheral arterial ischemia, as per standard of care, in the opinion of the investigator.
7. Untreated or uncontrolled hypertension, as per standard of care.
8. Poorly controlled diabetes, as per standard of care, in the opinion of the investigator.
9. Weight greater than 140 kg at the time of enrollment.
10. An existing history or suspicion of presence of hand or foot metastasis.
11. Use of other investigational devices or active compression/ cryotherapy interventions for CIPN prevention or management during the study.
12. Participants who are receiving neuropathy directed systemic therapies at the time of enrollment, namely, Pregabalin, Gabapentin, Amitriptyline, Nortriptyline, Venlafaxine, Duloxetine.
13. Participants who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with the requirements of the study.
14. Participants with cognitive impairment, psychiatric conditions, or mobility limitations that would prevent compliance with study procedures (e.g., inability to wear the device, complete questionnaires, or attend follow-up visits).
15. Current participation in a clinical study or within the last 30 days prior to screening that may cause peripheral neuropathy.
16. Participation in this study at an earlier stage.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Luminate Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palomar Medical Center Poway
Poway, California, United States
Hialeah Hospital
Hialeah, Florida, United States
Hawaii Cancer Care
Honolulu, Hawaii, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, United States
Health Partners Frauenshuh Cancer Center
Minneapolis, Minnesota, United States
Springfield Regional Cancer Center
Springfield, Ohio, United States
Mercy Health St. Elizabeth Hospital
Youngstown, Ohio, United States
Hospital Sisters Health System - St.Vincent & St.Mary's
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIN-53
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.